Skip to content
MARKETS / BALCAO / EVFM
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Evofem Biosciences, Inc. EVFM

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$20.2M
▲ 4.2% YoY
$391,000
$-2.0M
In brief

What this company does

Our first commercial product, PHEXX®, was approved by the FDA on May 22, 2020, for the prevention of pregnancy and launched in the U.S. in September 2020. We acquired global rights to SOLOSEC® on July 14, 2024 and relaunched the brand in November 2024. Evofem’s commercial operations are focused on the U.S., which is the largest commercial market worldwide and which we believe presents the greatest opportunity for PHEXX, SOLOSEC, and other women’s health products. As of February 28, 2026, we had a total of 29 full-time employees.

Written from the business description in Evofem Biosciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 March 2026. Every sentence was checked against that document before publication.

Growth
USD 20.2M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 20.2 · Net income 0.4
20M40M-80M-160M2013201520172019202120232025
Compound annual growth
+6.2%
+114.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +114.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
2 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 16.7% · Net 1.9%
-10000%-20000%-30000%2013201520172019202120232025
ROE
FY2020 · ROE -1675.9%
-500%-1000%-1500%2013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -2.0
-50M-100M2013201520172019202120232025
Net buybacks $ Dividends $
FY2022 · Dividends — · Net buybacks 18000.0
80000160000201820212022

Total assetsUSD 20.3M
EquityUSD -74.3M
CashUSD 578,000.00
Gross debtUSD 147,000.00
Net debtUSD -431,000.00
Current ratio0.18×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.0······
Operating income $B0.0−0.0−0.0−0.1−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.0−0.0−0.0··········
Income tax $B0.0·0.00.00.00.00.00.00.00.00.00.0·
Net income $B0.0−0.00.1−0.1−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0·−0.0−0.0−0.0
EPS, diluted $0.00−0.110.05−167.42−23.63−2.12−1.99−5.74−55.78−5.66−18.91−5.36−29.33
Dividend / sh $·············
Payout %·······−0·····
ROE %·····−1675.9····−96.9−252.9·
Shares out B0.130.110.020.000.010.080.050.030.000.000.010.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 39 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image